Argenx benefits from fresh UBS upgrade, shares supported by broad Buy consensus

By Christina Vogel, Background & Management desk. Reviewed prior to publication on 2026-06-22, 20:55.

Argenx (NL0010832176) continues to attract supportive analyst attention. UBS and BNP Paribas have each reiterated a Buy stance on the NASDAQ and Euronext Bruxelles listed biotech specialist in recent sessions, adding to an already dense Buy consensus according to MarketScreener and TrendMatrix.

What UBS and BNP Paribas signal

On MarketScreener, Argenx is highlighted as benefiting from a new note by UBS that maintains a positive view on the immunology player, underscoring confidence in its long-term growth profile on Euronext Bruxelles. On the same platform, BNP Paribas also reiterates a Buy recommendation, keeping its classification for the shares in place and aligning with other research houses that see value in the current level.

These latest calls come on top of a mid-June move in which Goldman Sachs lifted its price target for Argenx to 885 euros while keeping a Buy rating, a step that was documented in the detailed news stream for the stock. The cluster of Buy recommendations from UBS, BNP Paribas, Goldman Sachs, KBC Securities and William O'Neil, among others, provides a clear analyst anchor for investors watching the NASDAQ ticker ARGX alongside the Euronext Bruxelles line.

Consensus ahead of the July earnings date

Data compiled by TrendMatrix shows that 25 analysts currently cover Argenx, assigning an average rating equivalent to 4.2 out of 5, which corresponds to a broadly constructive stance on the stock. The same source cites an average price target around 1,022 US dollars per share for the NASDAQ listing, a level that stands above the recent closing price cluster in the high 870 dollar range from 2026-06-18.

TrendMatrix also lists the next earnings release and conference call for Argenx on 2026-07-23, around 32 days away, positioning the stock clearly on the near-term calendar for both NASDAQ and EURO STOXX 50 focused investors. In earlier coverage, AD HOC NEWS highlighted that this event is expected to update the market on commercial traction and pipeline progress in autoimmune diseases, themes that underlie many of the Buy arguments presented by UBS, Goldman Sachs and peers.

How Argenx earns its money

Argenx generates its revenue primarily from innovative antibody-based therapies in autoimmune diseases, with the FcRn antagonist efgartigimod marketed under the brand name Vyvgart as its flagship commercial product. Vyvgart is approved for generalized myasthenia gravis and is being developed in additional indications, while Argenx also advances a broader immunology pipeline through internal R&D and selected partnerships.

Where the Argenx shares trade today

The Argenx shares (NL0010832176) last closed on NASDAQ at 877.72 US dollars on 2026-06-18, based on TradingKey and TrendMatrix price data, while the parallel Euronext Bruxelles line most recently showed 796.00 euros on 2026-06-22.

This text is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell securities. Figures and dates are based on sources cited and may change. Investors should conduct their own research or consult a qualified financial advisor.